Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms

被引：0
|
作者：
Ryo Ariyasu
Noriko Yanagitani
Kenichi Tadokoro
Toshikazu Yamaguchi
Ken Uchibori
Satoru Kitazono
Naoya Fujita
Ryohei Katayama
Makoto Nishio
机构：
[1] The Cancer Institute Hospital,Department of Thoracic Medical Oncology
[2] Japanese Foundation for Cancer Research,Cancer Chemotherapy Center
[3] BML,undefined
[4] INC,undefined
[5] Japanese Foundation for Cancer Research,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2020年 / 86卷
关键词：
deletion polymorphism; single nucleotide polymorphism; Non-small cell lung cancer; EGFR-TKI;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：517 / 525
页数：8
相关论文
共 50 条
  • [21] Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations
    Igawa, Satoshi
    Ryuge, Shiichiro
    Ichinoe, Masaaki
    Nakashima, Hiroyasu
    Otani, Sakiko
    Nakahara, Yoshiro
    Fukui, Tomoya
    Sasaki, Jiichiro
    Kubota, Masaru
    Katagiri, Masato
    Murakumo, Yoshiki
    Satoh, Yukitoshi
    Sato, Yuichi
    Masuda, Noriyuki
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (1-2) : 7 - 13
  • [22] Prediction Model for Tumor Volume Nadir in EGFR-mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors
    Nishino, Mizuki
    Lu, Junwei
    Hino, Takuya
    Vokes, Natalie I.
    Janne, Pasi A.
    Hatabu, Hiroto
    Johnson, Bruce E.
    JOURNAL OF THORACIC IMAGING, 2023, 38 (02) : 82 - 87
  • [23] Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management
    Ruishan Wen
    Ying Chen
    Jinyu Long
    Xiulian Huang
    Yuxin Guo
    Baoquan Lin
    Zongyang Yu
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 8307 - 8316
  • [24] Aggressive progression to EGFR tyrosine kinase inhibitors in advanced NSCLC patients: concomitant mutations, prognostic indicator and subsequent management
    Wen, Ruishan
    Chen, Ying
    Long, Jinyu
    Huang, Xiulian
    Guo, Yuxin
    Lin, Baoquan
    Yu, Zongyang
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (11) : 8307 - 8316
  • [25] Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors
    Giaccone, Giuseppe
    Wang, Yisong
    CANCER TREATMENT REVIEWS, 2011, 37 (06) : 456 - 464
  • [26] Clinical development of EGFR-tyrosine kinase inhibitors in Japan
    Kazuhiko Nakagawa
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 33 - 37
  • [27] Clinical development of EGFR-tyrosine kinase inhibitors in Japan
    Nakagawa, Kazuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (Suppl 1) : S33 - S37
  • [28] EGFR tyrosine kinase inhibitors in lung cancer: An evolving story
    Sequist, Lecia V.
    Lynch, Thomas J.
    ANNUAL REVIEW OF MEDICINE, 2008, 59 : 429 - 442
  • [29] The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
    Lee, Ji Yun
    Ku, Bo Mi
    Lim, Sung Hee
    Lee, Min-Young
    Kim, Haesu
    Kim, Moonjin
    Kim, Sungmin
    Jung, Hyun Ae
    Sun, Jong-Mu
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) : 903 - 909
  • [30] FDG-PET for predicting efficacy of EGFR-tyrosine kinase inhibitors in lung cancer
    Noriaki Sunaga
    Kyoichi Kaira
    Takeshi Hisada
    Masanobu Yamada
    World Journal of Respirology, 2013, (03) : 104 - 109
12345